Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Reinnervate, Tecan Sign Marketing Deal

By Drug Discovery Trends Editor | June 8, 2012

Reinnervate Ltd and Tecan Trading AG have signed a co-marketing agreement to develop a range of automated solutions for 3D cell culture, based on the Freedom EVO liquid handling workstations and Reinnervate’s Alvetex Scaffold 3D cell culturing technology.

Alvetex products are based on a highly porous, polystyrene scaffold structure with a uniform and well¬defined architecture that provides an excellent environment for cells to acquire and maintain their natural three-dimensional shape and organization during incubation. The Alvetex Scaffold technology therefore gives more biologically relevant data by overcoming the limitations of traditional monolayer cultures. In combination with the flexibility and reliability of the Freedom EVO platform, it will provide powerful solutions for automated growth and maintenance of 3D cell cultures, allowing researchers to develop more reliable and powerful cellular assays.

Kevin Moore, Head of Applications and Solutions at Tecan, said: “We are delighted to be working with Reinnervate and look forward to combining our mutual expertise and technical abilities to develop ground-breaking solutions for cell biology customers.”

Richard Rowling, Commercial Director at Reinnervate added: “We are delighted that Tecan have decided to put Alvetex Scaffold at the heart of their plans for the automation of 3D cell culture. We believe that this agreement is great news for cell biologists, as Alvetex Scaffold is becoming the industry standard for scientists who need to retain the native structure and functionality of cells to better mimic in-vivo biological models.”

Date: June 7, 2012
Source: Reinnervate Ltd., Tecan Trading AG


Filed Under: Drug Discovery

 

Related Articles Read More >

NIH is reorganizing clinical trial funding by trial type instead of disease
Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE